Loading clinical trials...
Loading clinical trials...
Propranolol, Carvedilol and Rosuvastatin in the Prevention of Recurrent Variceal Haemorrhage in Patients With Cirrhotic Portal Hypertension
Patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to use propranolol or carvedilol. After 8 weeks, rosuvastatin or placebo will be blindly added to nonresponders (HVPG measurement \> 12mmHg) for another 8 weeks and hemodynamic response will be assessed again. Surrogate serum markers of portal hypertension will be evaluated and correlated to HVPG values and to its variations.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
Start Date
January 25, 2019
Primary Completion Date
December 20, 2020
Completion Date
December 20, 2022
Last Updated
May 14, 2019
80
ESTIMATED participants
Propranolol
DRUG
Carvedilol
DRUG
Rosuvastatin
DRUG
Placebo
DRUG
Lead Sponsor
Universidade Federal do Rio de Janeiro
NCT02417740
NCT05597488
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06932783